We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.94%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$977M
AUM Growth
+$166M
Cap. Flow
+$154M
Cap. Flow %
15.75%
Top 10 Hldgs %
25.96%
Holding
96
New
4
Increased
44
Reduced
31
Closed
7

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$31.5M
2
WBA
Walgreens Boots Alliance
WBA
+$16.4M
3
INCY icon
Incyte
INCY
+$15.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$13.2M
5
AET
Aetna Inc
AET
+$12.5M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$13.4M
2
BIIB icon
Biogen
BIIB
+$8.24M
3
CELG
Celgene Corp
CELG
+$7.12M
4
ABMD
Abiomed Inc
ABMD
+$5.83M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.72M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Financials 1.43%
3 Energy 0.15%
4 Technology 0.13%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
26
DELISTED
Esperion Therapeutics
ESPR
$15.9M 1.63%
406,361
+161,821
+66% +$8.18M
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
$15.3M 1.56%
230,000
+100,000
+77% +$5.73M
KYNB
28
Kyntra Bio
KYNB
$29.4M
$15M 1.53%
9,582
+2,800
+41% +$3.65M
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$14.9M 1.53%
1,051,933
+796,140
+311% +$13.2M
ONCE
30
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$14.7M 1.5%
177,600
+110,000
+163% +$8.49M
GKOS icon
31
Glaukos
GKOS
$10.6B
$14.6M 1.5%
360,000
-143,400
-28% -$5.1M
NVCR icon
32
NovoCure
NVCR
$1.91B
$14.1M 1.44%
450,000
+15,000
+3% +$417K
AGIO icon
33
Agios Pharmaceuticals
AGIO
$1.93B
$13.5M 1.38%
160,428
+65,428
+69% +$5.71M
PTLA
34
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$13.3M 1.36%
352,302
+82,054
+30% +$3.14M
ABT icon
35
Abbott
ABT
$187B
$12.9M 1.32%
212,000
+10,000
+5% +$606K
AET
36
DELISTED
Aetna Inc
AET
$12.8M 1.31%
+70,000
New +$12.5M
ARNA
37
DELISTED
Arena Pharmaceuticals Inc
ARNA
$12.4M 1.27%
284,621
-1,021
-0.4% -$43.9K
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.3M 1.26%
696,957
-95,773
-12% -$1.94M
ARRY
39
DELISTED
Array Biopharma Inc
ARRY
$12.1M 1.24%
723,370
+21,900
+3% +$348K
ALKS icon
40
Alkermes
ALKS
$8.25B
$11.9M 1.22%
290,000
+199,200
+219% +$9.07M
BSX icon
41
Boston Scientific
BSX
$71.5B
$11.4M 1.16%
347,968
– –
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$29.3B
$11.2M 1.15%
113,967
+30,000
+36% +$2.98M
IOVA icon
43
Iovance Biotherapeutics
IOVA
$2.87B
$10.8M 1.11%
847,476
-96,709
-10% -$1.41M
NBIX icon
44
Neurocrine Biosciences
NBIX
$16.6B
$10.8M 1.11%
110,377
+377
+0.3% +$33.7K
IMMU
45
DELISTED
Immunomedics Inc
IMMU
$10.8M 1.1%
455,330
+40,000
+10% +$804K
COR icon
46
Cencora
COR
$61.2B
$10.6M 1.08%
124,261
+20,000
+19% +$1.76M
EW icon
47
Edwards Lifesciences
EW
$51.7B
$9.95M 1.02%
205,092
-45,000
-18% -$2.1M
MYOK
48
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$9.84M 1.01%
198,272
+30,000
+18% +$1.45M
FLXN
49
DELISTED
Flexion Therapeutics, Inc.
FLXN
$9.09M 0.93%
351,786
+115,100
+49% +$2.99M
LIVN icon
50
LivaNova
LIVN
$4.2B
$8.48M 0.87%
85,000
+35,000
+70% +$3.18M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rhenman & Partners Asset Management held 96 positions worth $977M, up 20% from $811M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management deployed $154M of net new capital in Q2 2018, opening 4 new positions and adding to 44 existing holdings. Its largest new stake was Aetna Inc: 70,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was AbbVie, an estimated $13.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2018 buy was Aetna Inc: 70,000 shares worth $12.8M.
  • Rhenman & Partners Asset Management added most to Nektar Therapeutics in Q2 2018, an estimated $31.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2018 reduction was AbbVie, cutting an estimated $13.4M.
  • Rhenman & Partners Asset Management fully exited Endologix Inc in Q2 2018, selling an estimated $3.83M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $977M portfolio in Q2 2018.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 7 in Q2 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 20% quarter-over-quarter to $977M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2018, filed 20 Jul 2018.